Harmony Biosciences
HRMY
Market cap $2.04B

35.48 USD

+0.03

0.08%

At close Jul 30, 4:00 PM EDT

After hours

36.99

+1.51

4.26%

1 day

0.08%

5 days

-3.90%

1 month

12.28%

3 months

20.39%

6 months

-10.27%

Year to date

1.87%

1 year

4.75%

5 years

-4.13%

10 years

-4.13%

About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Employees: 268

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

215% more call options, than puts

Call options by funds: $4.95M | Put options by funds: $1.57M

116% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 19

18% more repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 84

9% more funds holding

Funds holding: 245 [Q4 2024] → 266 (+21) [Q1 2025]

5.03% less ownership

Funds ownership: 92.42% [Q4 2024] → 87.39% (-5.03%) [Q1 2025]

8% less capital invested

Capital invested by funds: $1.81B [Q4 2024] → $1.66B (-$152M) [Q1 2025]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$48

35%

upside

Avg. target

$52

47%

upside

High target

$61

72%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Truist Securities Danielle Brill	35%upside $48	Buy Initiated	21 Jul 2025
Deutsche Bank David Hoang	55%upside $55	Buy Maintained	10 Jul 2025
Oppenheimer Andreas Argyrides	72%upside $61	Outperform Assumed	2 Jun 2025
Mizuho Graig Suvannavejh	35%upside $48	Outperform Maintained	15 May 2025
Needham Ami Fadia	38%upside $49	Buy Reiterated	7 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about HRMY published over the past 30 days

Zacks Investment Research

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks Investment Research

5 High Earnings Yield Stocks to Tap Into Value Investing Gains

Unlock value with IAG, PAGP, HOPE, COMM and HRMY, five stocks with high earnings yields and strong growth signals.

5 High Earnings Yield Stocks to Tap Into Value Investing Gains

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-2483 (domestic) or 785-838-9284 (international), and reference passcode HRMYQ225. It is recommended that.

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

Zacks Investment Research

Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again

Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again

Zacks Investment Research

3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)

Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)

Zacks Investment Research

HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?

HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect?

Zacks Investment Research

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, July 17, 2025, at 10:00 a.m. ET. To register in advance, please use this link. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmace.

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

Zacks Investment Research

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

See News Rankings

Charts implemented using Lightweight Charts™